PPP2CB encodes the beta isoform of the catalytic subunit of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase (EC 3.1.3.16). PP2Acbeta is the minor catalytic isoform (~97% identical to the alpha isoform PPP2CA, which is ~10x more abundant). The catalytic subunit uses a bimetallic Mn2+ active site to dephosphorylate phosphoserine and phosphothreonine residues on protein substrates. PP2A functions as a heterotrimeric holoenzyme consisting of a scaffold A subunit, catalytic C subunit, and one of many regulatory B subunits that confer substrate specificity and subcellular localization. Combinatorial assembly of subunit isoforms generates >70 distinct PP2A holoenzymes. PP2Acbeta is predominantly cytoplasmic and nuclear, and is also a component of the STRIPAK complex. C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1) is a key regulatory mechanism controlling B subunit selection and holoenzyme assembly. PP2A opposes kinase signaling in numerous pathways including cell cycle, Wnt/beta-catenin, Ras/MAPK, NF-kappaB, and PI3K/Akt, and is a major regulator of tau phosphorylation in brain.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
|
GO:0004722
protein serine/threonine phosphatase activity
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: PPP2CB is a well-established serine/threonine phosphoprotein phosphatase. This is the core molecular function of the protein, supported by extensive biochemical evidence and phylogenetic analysis across eukaryotes. The IBA annotation is well supported by broad phylogenetic conservation.
Reason: This is the defining molecular function of PPP2CB. The protein catalyzes dephosphorylation of phosphoserine and phosphothreonine residues using a bimetallic active site. Supported by UniProt EC 3.1.3.16 assignment, deep research review, and phylogenetic inference.
Supporting Evidence:
PMID:8206937
Methylation of PP2Ac subunit, in vitro, increases its activity toward both phosphorylase a and a phosphopeptide.
PMID:2849765
The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A beta catalytic subunit.
|
|
GO:0000278
mitotic cell cycle
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: PP2A holoenzymes (with B55 and B56 regulatory subunits) play essential roles in mitotic cell cycle regulation, opposing CDK-mediated phosphorylation during cell cycle transitions. The IBA annotation is phylogenetically well-supported.
Reason: PP2A is a central regulator of mitotic cell cycle progression. PP2A-B55 and PP2A-B56 are required for mitotic exit, opposing CDK substrates. UniProt lists roles in kinetochore/centromere and spindle pole localization during mitosis. The phylogenetic inference is appropriate.
Supporting Evidence:
PMID:27880917
complementary affinity purification and proximity-based interaction proteomics approaches to generate a physical interactome for 140 human proteins harboring phosphatase catalytic domains
|
|
GO:0005829
cytosol
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: PPP2CB is active in the cytosol, consistent with its role as a major cytoplasmic phosphatase. The IBA annotation is well supported by both phylogenetic evidence and experimental localization data.
Reason: Cytosolic localization of PP2A catalytic subunits is well established. UniProt lists cytoplasm as a subcellular location for PPP2CB. Reactome pathways also place PPP2CB in cytosol for various signaling events.
Supporting Evidence:
PMID:16541025
PP2A colocalizes with shugoshin at centromeres and is required for centromeric protection.
|
|
GO:0000775
chromosome, centromeric region
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: IEA annotation derived from UniProt subcellular location vocabulary. UniProt cites PMID:16541025 (Kitajima et al. 2006) showing PP2A localizes to centromeres in prometaphase cells via interaction with SGO1.
Reason: The localization is experimentally supported. UniProt states: "In prometaphase cells, but not in anaphase cells, localizes at centromeres." This is based on PMID:16541025 which directly demonstrated PP2A-SGO1 interaction at centromeres.
Supporting Evidence:
PMID:16541025
a specific subtype of serine/threonine protein phosphatase 2A (PP2A) associating with human shugoshin. PP2A colocalizes with shugoshin at centromeres
|
|
GO:0000922
spindle pole
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: IEA from UniProt subcellular location. UniProt states PP2A is found at spindle poles during mitosis, based on PMID:16541025.
Reason: Spindle pole localization during mitosis is documented in UniProt subcellular location, which cites PMID:16541025. Consistent with PP2A role in mitotic regulation.
Supporting Evidence:
PMID:16541025
crucial--particularly at centromeres--for proper chromosome segregation in mitosis and meiosis
|
|
GO:0004722
protein serine/threonine phosphatase activity
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: Combined automated annotation from multiple IEA methods confirming protein serine/threonine phosphatase activity. Redundant with IBA and TAS annotations for the same term but independently valid.
Reason: Correct core function. This IEA annotation is consistent with the more authoritative IBA and TAS annotations for the same GO term.
|
|
GO:0005634
nucleus
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: IEA from UniProt subcellular location. PPP2CB has been experimentally shown to localize to the nucleus, consistent with its role in nuclear phosphatase activity and its description as predominantly cytoplasmic and nuclear.
Reason: Nuclear localization is well supported. UniProt cites PMID:16541025 and also states PPP2CB is nucleoplasmic (IDA from HPA). Deep research confirms PPP2CB is predominantly cytoplasmic and nuclear.
Supporting Evidence:
PMID:16541025
PP2A colocalizes with shugoshin at centromeres and is required for centromeric protection
|
|
GO:0005737
cytoplasm
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: IEA annotation for cytoplasm localization. Broader than cytosol but still correct. PPP2CB is well established as a cytoplasmic protein.
Reason: Cytoplasm is a broader parent term of cytosol. PPP2CB is well established in both cytosol and cytoplasm. Consistent with IBA cytosol annotation and UniProt subcellular location.
|
|
GO:0016787
hydrolase activity
|
IEA
GO_REF:0000002 |
ACCEPT |
Summary: IEA from InterPro domain mapping. Hydrolase activity is correct but too general for a protein whose specific phosphatase activity is well characterized. The more specific GO:0004722 annotations exist.
Reason: While very broad, hydrolase activity is technically correct as a parent of phosphatase activity. The more specific GO:0004722 annotations also exist. This IEA is acceptable as a domain-based annotation even though more informative terms are present.
|
|
GO:0090443
FAR/SIN/STRIPAK complex
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: IEA from ARBA machine learning model predicting STRIPAK complex membership. This is consistent with experimental evidence from PMID:18782753 (IDA annotation also present).
Reason: Correct annotation. PPP2CB was experimentally identified as part of the STRIPAK complex in PMID:18782753, and a separate IDA annotation exists. This IEA is redundant but valid.
|
|
GO:0005515
protein binding
|
IPI
PMID:10698523 GSK-3beta-dependent phosphorylation of adenomatous polyposis... |
MARK AS OVER ANNOTATED |
Summary: IPI based on interaction with AXIN2 (Q9Y2T1). The study showed PP2A complexed with Axin dephosphorylates APC in Wnt signaling. The interaction is functionally meaningful (Wnt pathway regulation) but annotated as generic protein binding.
Reason: Protein binding is uninformative. The interaction with AXIN2 reflects PP2A recruitment to the beta-catenin destruction complex. A more informative annotation would capture the specific functional context (e.g., phosphatase activity in the Wnt pathway), but that is a BP annotation, not MF. The IPI evidence does not support a more specific MF term than protein binding.
Supporting Evidence:
PMID:10698523
the heterodimeric form of protein phosphatase 2A (PP2A) directly bound to Axin, and PP2A complexed with Axin dephosphorylated APC phosphorylated by GSK-3beta
|
|
GO:0005515
protein binding
|
IPI
PMID:16085932 A novel, evolutionarily conserved protein phosphatase comple... |
MARK AS OVER ANNOTATED |
Summary: IPI based on interaction with TIPRL (O75663). The study characterized a PP4 complex involved in cisplatin sensitivity. TIPRL is a known PP2A interactor and phosphatase regulator. Annotated as generic protein binding.
Reason: Protein binding is uninformative. TIPRL interaction with PP2A catalytic subunits is part of the phosphatase regulatory network, but the GO term does not capture the functional significance. The primary study focused on PP4, not PP2A.
Supporting Evidence:
PMID:16085932
Using a combination of tandem affinity purification tagging and mass spectrometry, we characterized a novel, evolutionarily conserved protein phosphatase 4 (PP4)-containing complex
|
|
GO:0005515
protein binding
|
IPI
PMID:18782753 A PP2A phosphatase high density interaction network identifi... |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with IGBP1/alpha4 (P78318) and STRIP1 (Q5VSL9) from the PP2A high-density interaction network study that defined the STRIPAK complex. These are well-established PP2A complex components.
Reason: Protein binding is uninformative. Both IGBP1 and STRIP1 are functional PP2A-associated proteins. The interactions are better captured by the STRIPAK complex (GO:0090443) and PP2A complex (GO:0000159) annotations.
Supporting Evidence:
PMID:18782753
STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated protein Mob3, the novel proteins STRIP1 and STRIP2
|
|
GO:0005515
protein binding
|
IPI
PMID:19156129 An integrated workflow for charting the human interaction pr... |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with IGBP1 (P78318) from an integrated PP2A interaction proteomics workflow. This is a well-characterized PP2A regulatory interaction.
Reason: Protein binding is uninformative. IGBP1/alpha4 is a known PP2A chaperone/regulatory protein. Better captured by complex membership annotations.
|
|
GO:0005515
protein binding
|
IPI
PMID:20969868 LIM domain protein FHL1B interacts with PP2A catalytic β sub... |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with FHL1B (Q13642-2). Study demonstrated FHL1B specifically interacts with PP2A catalytic beta subunit (PPP2CB) by yeast two-hybrid and co-immunoprecipitation, suggesting a novel cell-cycle regulatory pathway.
Reason: Protein binding is uninformative. The FHL1B interaction is PPP2CB-specific (not shown for PPP2CA) and linked to cell cycle regulation, which is interesting but the GO term does not capture this specificity.
Supporting Evidence:
PMID:20969868
FHL1B was demonstrated to interact with the beta catalytic subunit (Cbeta) of a type 2A protein phosphatase (PP2A) by yeast two-hybrid screening
|
|
GO:0005515
protein binding
|
IPI
PMID:25531779 STRIPAK components determine mode of cancer cell migration a... |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with STRIP1 (Q5VSL9) from STRIPAK complex study on cancer cell migration and metastasis. High-throughput proteomics study.
Reason: Protein binding is uninformative. STRIP1 interaction is part of STRIPAK complex, better captured by GO:0090443.
|
|
GO:0005515
protein binding
|
IPI
PMID:26496610 A human interactome in three quantitative dimensions organiz... |
MARK AS OVER ANNOTATED |
Summary: IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from quantitative human interactome study. Large-scale proteomics.
Reason: Protein binding is uninformative. Both are known PP2A complex components. High-throughput study; interactions better captured by complex annotations.
|
|
GO:0005515
protein binding
|
IPI
PMID:27880917 Phenotypic and Interaction Profiling of the Human Phosphatas... |
MARK AS OVER ANNOTATED |
Summary: IPI for interactions with TIPRL (O75663) and IGBP1 (P78318) from comprehensive phosphatase interactome profiling. Study identified diverse mitotic regulators among phosphatase interactors.
Reason: Protein binding is uninformative. Both TIPRL and IGBP1 are established PP2A regulators. The study provides valuable interactome data but protein binding does not convey functional information.
Supporting Evidence:
PMID:27880917
complementary affinity purification and proximity-based interaction proteomics approaches to generate a physical interactome for 140 human proteins harboring phosphatase catalytic domains
|
|
GO:0005515
protein binding
|
IPI
PMID:28514442 Architecture of the human interactome defines protein commun... |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with STRIP1 (Q5VSL9) from architecture of the human interactome study. Large-scale proteomics.
Reason: Protein binding is uninformative. STRIP1 is a STRIPAK component. High-throughput study.
|
|
GO:0005515
protein binding
|
IPI
PMID:32814053 Interactome Mapping Provides a Network of Neurodegenerative ... |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with FMR1/FMRP (Q06787-7) from neurodegenerative disease interactome mapping study. The interaction was identified by mass spectrometry in a large-scale screen.
Reason: Protein binding is uninformative. The FMR1 interaction is from a high-throughput screen and the functional significance for PPP2CB is unclear. PP2A may dephosphorylate FMRP but this is not demonstrated in this study.
Supporting Evidence:
PMID:32814053
Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains
|
|
GO:0005515
protein binding
|
IPI
PMID:33961781 Dual proteome-scale networks reveal cell-specific remodeling... |
MARK AS OVER ANNOTATED |
Summary: IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from dual proteome-scale cell-specific interactome study.
Reason: Protein binding is uninformative. Both are established PP2A complex members. High-throughput study.
|
|
GO:0005515
protein binding
|
IPI
PMID:35271311 OpenCell: Endogenous tagging for the cartography of human ce... |
MARK AS OVER ANNOTATED |
Summary: IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from the OpenCell endogenous tagging study. Large-scale proteomics.
Reason: Protein binding is uninformative. Both are known PP2A/STRIPAK complex members. High-throughput study.
|
|
GO:0005515
protein binding
|
IPI
PMID:9647778 Alpha 4 associates with protein phosphatases 2A, 4, and 6. |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with IGBP1/alpha4 (P78318). Study demonstrated alpha4 associates constitutively with both PP2A catalytic isoforms, PP4C, and PP6C. This is a well-established functional interaction where alpha4 serves as a chaperone protecting monomeric PP2A C subunit.
Reason: Protein binding is uninformative. The alpha4-PP2Ac interaction is functionally important for PP2A biogenesis and stability. However, the GO term protein binding does not capture this functional role.
Supporting Evidence:
PMID:9647778
alpha 4, a previously identified phosphoprotein, associates constitutively with the catalytic subunits of PP4, PP6, and both isoforms of PP2A
|
|
GO:0000159
protein phosphatase type 2A complex
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA from Ensembl Compara transfer from mouse PPP2CB. PPP2CB is a catalytic subunit of the PP2A holoenzyme complex, which is its primary functional context.
Reason: Core annotation. PPP2CB is a defining component of the PP2A holoenzyme complex. Strongly supported by extensive biochemical and structural evidence. Also has a TAS annotation (PMID:8206937).
|
|
GO:0004721
phosphoprotein phosphatase activity
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA from Ensembl Compara. Phosphoprotein phosphatase activity is a parent term of protein serine/threonine phosphatase activity (GO:0004722). Correct but less specific than GO:0004722.
Reason: Technically correct as PPP2CB does have phosphoprotein phosphatase activity. More specific GO:0004722 annotations are also present. This broader IEA is acceptable.
|
|
GO:0010288
response to lead ion
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: IEA transferred from rat PPP2CB (P62716) via Ensembl Compara. Based on rat studies showing PP2A activity is affected by lead exposure. Duplicate with ISS annotation below.
Reason: Response to lead ion is not a core function of PPP2CB. Lead ions can inhibit PP2A activity (as they affect many metalloenzymes), but this is a toxicological response rather than a primary biological function. Keeping as non-core given the supporting evidence from rat studies.
|
|
GO:0031113
regulation of microtubule polymerization
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: IEA transferred from rat PPP2CB via Ensembl Compara. PP2A regulates microtubule dynamics through dephosphorylation of MAPs (MAP1b, MAP2, tau). This is consistent with PP2A's role in cytoskeletal regulation.
Reason: PP2A regulates microtubule polymerization indirectly by dephosphorylating microtubule-associated proteins. PMID:10640627 showed PP2A regulates MAP1b and MAP2 phosphorylation and their microtubule binding activity. This is a downstream consequence of PP2A phosphatase activity rather than a core function of PPP2CB specifically.
Supporting Evidence:
PMID:10640627
The inhibition of PP2A, and to a lesser extent of PP2B, was found to induce an increased phosphorylation of MAP1b and inhibit its microtubule binding activity
|
|
GO:0044325
transmembrane transporter binding
|
IEA
GO_REF:0000107 |
UNDECIDED |
Summary: IEA transferred from rat PPP2CB via Ensembl Compara. PP2A interacts with various membrane transporters and channels to regulate their phosphorylation state. Limited direct evidence for PPP2CB specifically.
Reason: The evidence for transmembrane transporter binding is based on computational transfer from rat. While PP2A can regulate transporter phosphorylation, the specificity and directness of a binding interaction is not well documented for PPP2CB specifically. Unable to verify the original rat experimental evidence.
|
|
GO:0046580
negative regulation of Ras protein signal transduction
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: IEA transferred from rat PPP2CB via Ensembl Compara. PP2A dephosphorylates components of the Ras/MAPK pathway, acting as a negative regulator. This is well established for PP2A holoenzymes generally.
Reason: PP2A is well established as a negative regulator of Ras/MAPK signaling, including dephosphorylation of RAF and ERK pathway components. However, this represents one of many PP2A-regulated pathways and is driven by specific B subunit combinations rather than PPP2CB specifically. Deep research review confirms PP2A antagonizes Ras/MAPK signaling.
|
|
GO:0005654
nucleoplasm
|
IDA
GO_REF:0000052 |
ACCEPT |
Summary: IDA from HPA immunofluorescence data. PPP2CB was detected in nucleoplasm by immunofluorescence. Consistent with UniProt subcellular location annotation showing nuclear localization.
Reason: Nucleoplasm localization is experimentally supported by HPA immunofluorescence and consistent with UniProt subcellular location showing nuclear localization (PMID:16541025). Deep research also describes PPP2CB as predominantly cytoplasmic and nuclear.
|
|
GO:1902996
regulation of neurofibrillary tangle assembly
|
TAS
PMID:16262633 Contributions of protein phosphatases PP1, PP2A, PP2B and PP... |
KEEP AS NON CORE |
Summary: TAS annotation based on a study showing PP2A is the major tau phosphatase in human brain (~71% of total tau phosphatase activity), and PP2A activity is decreased in AD brain, correlating with tau hyperphosphorylation and neurofibrillary tangle formation.
Reason: While PP2A is clearly the major tau phosphatase, this represents a downstream physiological consequence of PP2A phosphatase activity in brain rather than a core function of PPP2CB. Additionally, the study used PP2A generally (likely predominantly PPP2CA given its higher expression in brain). The annotation is not wrong but represents a non-core, tissue-specific function.
Supporting Evidence:
PMID:16262633
PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately 11%, approximately 10% and approximately 7%, respectively, of the total tau phosphatase activity of human brain
|
|
GO:0043124
negative regulation of canonical NF-kappaB signal transduction
|
IGI
PMID:28159925 miRNA-1246 induces pro-inflammatory responses in mesenchymal... |
KEEP AS NON CORE |
Summary: IGI annotation from a study showing miR-1246 directly targets PPP2CB, and PPP2CB knockdown increases p65/NF-kappaB levels in MSCs. The IGI evidence is based on interaction with RELA/p65 (Q04206).
Reason: The study provides evidence that PPP2CB negatively regulates NF-kappaB signaling, but in a specific cellular context (MSCs in tumor microenvironment). PPP2CB knockdown increased RELA expression and total p65 levels but did not directly increase phospho-p65. The effect on pro-inflammatory cytokines required additional TNFalpha stimulation. This represents a non-core, context-dependent function.
Supporting Evidence:
PMID:28159925
Knock-down of PPP2CB significantly increased RELA expression
PMID:28159925
knock-down of either PRKAR1A or PPP2CB led to a significant up-regulation of total p65 in MSCs whereas phosphorylation of p65 at Ser536 remained unaffected
|
|
GO:0090443
FAR/SIN/STRIPAK complex
|
IDA
PMID:18782753 A PP2A phosphatase high density interaction network identifi... |
ACCEPT |
Summary: IDA annotation showing PPP2CB is part of the STRIPAK complex, based on iterative affinity purification/mass spectrometry in human cells. The study defined the STRIPAK complex and identified PPP2CB as a core component.
Reason: Well-supported experimental evidence. The study used iterative AP-MS to identify PPP2CB in the STRIPAK complex, which contains PP2A catalytic and scaffolding subunits, striatins, MOB4, STRIP1/2, PDCD10, and STE20 kinases. This is a core complex for PPP2CB function.
Supporting Evidence:
PMID:18782753
STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated protein Mob3, the novel proteins STRIP1 and STRIP2
|
|
GO:0010629
negative regulation of gene expression
|
IGI
PMID:28159925 miRNA-1246 induces pro-inflammatory responses in mesenchymal... |
MARK AS OVER ANNOTATED |
Summary: IGI annotation (with TNFalpha P01375) showing PPP2CB acts upstream of negative regulation of gene expression. Based on the miR-1246/PPP2CB study in MSCs where PPP2CB knockdown combined with TNFalpha enhanced expression of pro-inflammatory genes.
Reason: This annotation is overly broad. The study showed PPP2CB knockdown combined with TNFalpha increases IL-6, CCL2, CCL5 transcription in MSCs. This means PPP2CB normally negatively regulates expression of these specific inflammatory genes, but the term "negative regulation of gene expression" is too generic. Additionally, the qualifier is acts_upstream_of rather than involved_in, indicating indirect effects.
Supporting Evidence:
PMID:28159925
knock-down of PPP2CB in combination with TNFalpha stimulation phenocopied the miR-1246-enhanced transcriptional response of IL-6
|
|
GO:0010629
negative regulation of gene expression
|
IMP
PMID:28159925 miRNA-1246 induces pro-inflammatory responses in mesenchymal... |
MARK AS OVER ANNOTATED |
Summary: IMP annotation showing PPP2CB is involved in negative regulation of gene expression, based on the same miR-1246 study in MSCs.
Reason: Same concern as the IGI annotation above. The term is too broad. The evidence shows PPP2CB normally suppresses inflammatory gene expression in MSCs, but this is a very general biological process annotation that does not capture specificity. The NF-kappaB annotation (GO:0043124) is more specific and informative.
Supporting Evidence:
PMID:28159925
knock-down of PPP2CB significantly decreased releases of IL-6 and CCL2
|
|
GO:0010804
negative regulation of tumor necrosis factor-mediated signaling pathway
|
IGI
PMID:28159925 miRNA-1246 induces pro-inflammatory responses in mesenchymal... |
KEEP AS NON CORE |
Summary: IGI annotation showing PPP2CB acts upstream of negative regulation of TNF-mediated signaling. Based on the miR-1246 study where PPP2CB knockdown combined with TNFalpha enhances inflammatory responses.
Reason: The evidence supports that PPP2CB negatively regulates TNF-mediated signaling in MSCs. PPP2CB knockdown released negative feedback on IL-6 transcription after TNFalpha stimulation. However, this is a context-dependent effect in MSCs and represents a non-core function.
Supporting Evidence:
PMID:28159925
knock-down of PPP2CB in combination with TNFalpha stimulation phenocopied the miR-1246-enhanced transcriptional response of IL-6 in combination with TNFalpha
|
|
GO:0004722
protein serine/threonine phosphatase activity
|
TAS
PMID:8206937 The catalytic subunit of protein phosphatase 2A is carboxyl-... |
ACCEPT |
Summary: TAS annotation from the study that demonstrated carboxyl methylation of PP2A catalytic subunit in vivo. The paper confirms PP2Ac phosphatase activity toward phosphorylase a and phosphopeptide substrates.
Reason: Core molecular function, directly supported by the cited publication which demonstrated PP2Ac enzymatic activity.
Supporting Evidence:
PMID:8206937
Methylation of PP2Ac subunit, in vitro, increases its activity toward both phosphorylase a and a phosphopeptide
|
|
GO:0048156
tau protein binding
|
NAS
PMID:28386764 Roles of tau protein in health and disease. |
KEEP AS NON CORE |
Summary: NAS annotation based on a comprehensive review of tau protein roles in health and disease. PP2A is well established as the major tau phosphatase, which implies physical binding to tau.
Reason: PP2A does bind and dephosphorylate tau protein, but this is primarily documented for PP2A holoenzymes in brain (likely predominantly PPP2CA-containing). The NAS evidence from a review article is weak. Tau binding is a substrate interaction for PP2A rather than a core binding function. Keeping as non-core given that PP2A-tau interaction is well established in the broader literature.
Supporting Evidence:
PMID:28386764
Tau is well established as a microtubule-associated protein in neurons
PMID:16262633
PP2A is the major tau phosphatase that regulates its phosphorylation at multiple sites in human brain
|
|
GO:0010288
response to lead ion
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation transferred from rat PPP2CB (P62716) by curator judgment. PP2A activity can be affected by lead exposure, as lead interferes with the metalloenzyme's active site.
Reason: Consistent with the IEA annotation for the same term. Response to lead ion is a toxicological response rather than a core function. The ISS transfer from rat is appropriate given near-identical sequence.
|
|
GO:0004722
protein serine/threonine phosphatase activity
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation transferred from rat PPP2CB (P62716). Core phosphatase activity, redundant with other annotations for the same term.
Reason: Correct core function. ISS transfer from rat is fully appropriate given near-100% sequence identity between human and rat PPP2CB.
|
|
GO:0004722
protein serine/threonine phosphatase activity
|
TAS
PMID:10640627 Regulation of phosphorylation of neuronal microtubule-associ... |
ACCEPT |
Summary: TAS annotation from a study on PP2A regulation of MAP1b and MAP2 phosphorylation in rat brain. Confirms PP2A serine/threonine phosphatase activity toward neuronal substrates.
Reason: Core molecular function. The study directly demonstrated PP2A phosphatase activity toward MAP substrates.
Supporting Evidence:
PMID:10640627
PP2A might be the major PP that participates in regulation of the phosphorylation of MAP1b and MAP2 and their biological activities
|
|
GO:0004722
protein serine/threonine phosphatase activity
|
TAS
PMID:16262633 Contributions of protein phosphatases PP1, PP2A, PP2B and PP... |
ACCEPT |
Summary: TAS annotation from the tau phosphorylation study. PP2A accounts for ~71% of tau phosphatase activity in human brain.
Reason: Core molecular function. The study quantitatively demonstrated PP2A phosphatase activity toward tau.
Supporting Evidence:
PMID:16262633
PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately 11%, approximately 10% and approximately 7%, respectively, of the total tau phosphatase activity of human brain
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1295599 |
ACCEPT |
Summary: TAS from Reactome pathway for SPRY2 translocation to plasma membrane. Places PPP2CB in cytosol as part of Spry regulation of FGF signaling.
Reason: Cytosol localization is correct and well-supported. Reactome annotation reflects PPP2CB involvement in SPRY2/FGF signaling regulation in the cytosol.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1295609 |
ACCEPT |
Summary: TAS from Reactome pathway for SRC phosphorylation of SPRY2. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations but valid from Reactome evidence.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1295613 |
ACCEPT |
Summary: TAS from Reactome pathway for SPRY2-GRB2 binding. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations but valid.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1295622 |
ACCEPT |
Summary: TAS from Reactome pathway for SPRY2-CBL binding. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations but valid.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1295632 |
ACCEPT |
Summary: TAS from Reactome pathway for PP2A dephosphorylation of SPRY2. This directly reflects PP2A phosphatase activity in the cytosol acting on the SPRY2 substrate.
Reason: Cytosol localization is correct and directly relevant to PP2A function. This Reactome entry describes the actual dephosphorylation reaction catalyzed by PP2A on SPRY2.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1549564 |
ACCEPT |
Summary: TAS from Reactome pathway for PTPN11 dephosphorylation of SPRY2. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-934559 |
ACCEPT |
Summary: TAS from Reactome pathway for SPRY2 phosphorylation by MNK1. Places PPP2CB in cytosol.
Reason: Cytosol localization is correct. Redundant with other cytosol annotations.
|
|
GO:0005515
protein binding
|
IPI
PMID:21784977 Zinc finger protein tristetraprolin interacts with CCL3 mRNA... |
MARK AS OVER ANNOTATED |
Summary: IPI for interaction with TTP/ZFP36 (P26651). The study focused on TTP regulation of CCL3 mRNA and tissue inflammation. The interaction with PPP2CB was likely identified as part of a broader interactome screen.
Reason: Protein binding is uninformative. The TTP-PPP2CB interaction may reflect PP2A regulation of TTP phosphorylation (TTP activity is regulated by phosphorylation), but the study focused on TTP-mRNA interactions, not PP2A function.
Supporting Evidence:
PMID:21784977
Zinc finger protein tristetraprolin (TTP) modulates macrophage inflammatory activity by destabilizing cytokine mRNAs
|
|
GO:0000159
protein phosphatase type 2A complex
|
TAS
PMID:8206937 The catalytic subunit of protein phosphatase 2A is carboxyl-... |
ACCEPT |
Summary: TAS annotation from the carboxyl-methylation study, which demonstrated PP2A exists as a complex with methylated catalytic subunit. The study worked with PP2A holoenzyme from MCF7 cells.
Reason: Core annotation. PPP2CB is a defining component of the PP2A complex. The study directly worked with PP2A holoenzyme complexes.
Supporting Evidence:
PMID:8206937
Treatment of extracts from human breast cancer (MCF7) cells with either alkali or ethanol increased immunoreactivity of PP2Ac subunit severalfold
|
|
GO:0006470
protein dephosphorylation
|
TAS
PMID:2849765 The nucleotide sequence of the cDNA encoding the human lung ... |
ACCEPT |
Summary: TAS annotation from the original cDNA cloning paper for human PPP2CB. The paper established PPP2CB as a phosphatase catalytic subunit.
Reason: Core biological process. Protein dephosphorylation is the fundamental reaction catalyzed by PPP2CB. This is directly supported by the identification of PPP2CB as a PP2A catalytic subunit.
Supporting Evidence:
PMID:2849765
The nucleotide sequence of the cDNA encoding the human lung protein phosphatase 2A beta catalytic subunit
|
|
GO:0046872
metal ion binding
|
IEA
GO_REF:0000043 |
NEW |
Summary: PPP2CB requires two Mn2+ ions at its active site for catalytic activity. Metal ion binding is inherent to its phosphatase mechanism. This annotation is present in UniProt GO lines but was not in the GOA TSV extract; adding as it appears in UniProt.
Reason: PPP2CB uses a bimetallic Mn2+ active site for catalysis. UniProt lists multiple Mn2+ binding sites (residues 57, 59, 85, 117, 167, 241) and includes metal ion binding as a GO annotation. This is a core aspect of the catalytic mechanism.
Supporting Evidence:
PMID:10318862
substitution of glutamine for either of two putative active site histidines in the PP2A C subunit results in inactivation of PP2A
|
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The literature reviewed matches the UniProt-provided target:
These checks support that the evidence below pertains to the intended human PPP2CB protein, rather than a paralog or non-human homolog. (cohen2010phosphatasefamiliesdephosphorylating pages 5-6, goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)
PPP2CB encodes the catalytic Cβ subunit of protein phosphatase 2A (PP2A), a major member of the PPP family of serine/threonine phosphatases. PP2A catalytic subunits (PPP2CA/PPP2CB) are extremely conserved across eukaryotes and contribute to the bulk of Ser/Thr dephosphorylation in cells when assembled into regulated holoenzymes. (cohen2010phosphatasefamiliesdephosphorylating pages 8-9, kokot2022emerginginsightsinto pages 1-2)
PP2A is typically a heterotrimeric holoenzyme composed of:
This A–C–B architecture is repeatedly emphasized as the key determinant of specificity: regulatory B subunits largely determine substrate specificity and subcellular localization. (nasa2020effectsofcarboxylterminal pages 1-3, peris2023regulationandrole pages 1-2)
Quantitatively, reviews summarize that combinatorial assembly yields >70–90 (and up to ~100) distinct PP2A holoenzymes, depending on how B-subunit isoforms/splice variants are counted. (cohen2010phosphatasefamiliesdephosphorylating pages 7-8, nasa2020effectsofcarboxylterminal pages 1-3, goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)
PP2A catalytic subunits are metal-dependent phosphoprotein phosphatases. Mechanistic descriptions from modern modeling and review sources converge on a bimetal active site (M1/M2) that coordinates the substrate phosphate and activates a bridging hydroxide (W1(OH−)) that attacks the phosphorus atom during hydrolysis of phospho-Ser/Thr bonds. (salter2023quantumbasedmodelingimplies pages 1-2, kokot2022emerginginsightsinto pages 6-7)
A 2023 quantum-based modeling analysis further proposes that a conserved catalytic-subunit arginine (Arg89) can enhance catalysis by bidentate binding to the substrate phosphate, lowering the computed activation barrier from 18.8 kcal/mol (Arg89 sequestered) to 15.5 kcal/mol (bidentate Arg89–substrate binding). (salter2023quantumbasedmodelingimplies pages 1-2)
A 2023 Trends in Biochemical Sciences review synthesizes current thinking that PPP phosphatase specificity arises from both:
For PP2A holoenzymes, B subunits are central: acidic patches on B55/B56 can promote dephosphorylation of sites with surrounding basic residues; B55 is discussed as targeting proline-directed sites (pSP/pTP) in specific conformations and can be regulated by prolyl isomerization. (nguyen2023substrateandphosphorylation pages 3-4)
Multiple sources emphasize that although PPP2CA and PPP2CB are very similar (~97%), they are not fully redundant and can differ by expression patterns and functional context. (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3)
In brain-related contexts, expression of Cα is generally higher than Cβ, suggesting PPP2CB may contribute a smaller fraction of total PP2A catalytic capacity in many settings but still be functionally important where it is expressed or recruited into specific holoenzymes. (verbinnen2021proteinphosphatase2a pages 1-5)
A therapeutics-focused PP2A review states that catalytic isoforms differ in localization: Cα (PPP2CA) is enriched at the plasma membrane, whereas Cβ (PPP2CB) is predominantly cytoplasmic and nuclear. (baskaran2018proteinphosphatase2a pages 6-10)
This provides a plausible functional axis for PPP2CB annotation: PPP2CB-containing holoenzymes may contribute disproportionately to nuclear and cytoplasmic dephosphorylation events, depending on recruited B subunits and signaling context. (baskaran2018proteinphosphatase2a pages 6-10, peris2023regulationandrole pages 1-2)
Key regulatory principles apply to both catalytic isoforms (and are typically described for PP2A-Cα but explicitly framed as PP2Acα/β in several sources):
A 2024 PNAS study provides cryo-EM structures of PP2A-B56δ showing that B56δ contains long intrinsically disordered N/C-terminal arms that fold back onto the holoenzyme, forming a dynamic interface spanning >190 Å. This interface occludes the active site/substrate-binding region and stabilizes a closed, autoinhibited state, providing a concrete structural model for regulation by phosphorylation and for disease-mutation effects (Jordan’s syndrome; PPP2R5D variants). (wu2024b56δlongdisorderedarms pages 1-2)
Although this work focuses on the regulatory subunit PPP2R5D, it explicitly frames the catalytic core as PP2Ac (PPP2CA/PPP2CB) and thus is directly relevant to PPP2CB-containing holoenzymes operating with B56δ. (wu2024b56δlongdisorderedarms pages 1-2)
A 2023 BBA Reviews on Cancer article summarizes how PP2A-B56 tumor suppressor functions depend on regulated holoenzyme assembly, strongly influenced by C-terminal tail modifications (phosphorylation and Leu309 methylation) and by assembly factors such as PTPA and PME-1. It also highlights that PME-1 can directly suppress PP2A by displacing metal ions from the active site, adding mechanistic depth beyond “methylation changes binding.” (peris2023regulationandrole pages 2-4)
The 2023 TiBS review emphasizes that PPP holoenzymes (including PP2A with PPP2CA/PPP2CB) achieve specificity via combined consensus motifs and SLiM docking, and that modern mass spectrometry approaches are transforming substrate mapping. (nguyen2023substrateandphosphorylation pages 1-3)
A 2024 Scientific Reports study using plasma and duodenal proteomics in celiac disease identified PPP2CB as one of four plasma proteins selected by three machine-learning methods (alongside FABP, CPOX, BHMT) as potentially associated with pathological grading (Marsh classification/villous atrophy). (li2024proteomicanalysisof pages 6-8, li2024proteomicanalysisof pages 9-10)
Notably, the same analysis reports that PPP2CB’s ROC performance was limited in that cohort: AUC 0.5661 with 95% CI 0.4225–0.7097 and P>0.05, indicating that PPP2CB is best interpreted as a hypothesis-generating feature rather than a validated biomarker. (li2024proteomicanalysisof pages 6-8)
Because PPP2CB encodes a catalytic subunit that functions within many alternative PP2A holoenzymes, pathway attribution is best made at the holoenzyme-family level (B55, B56, etc.), with PPP2CB contributing as the catalytic engine when present.
Reviews emphasize that PP2A-B55 and PP2A-B56 oppose kinase signaling during cell-cycle transitions, with substrate selection shaped by B-subunit docking and motif preferences; PP2A-B55 is frequently discussed in the context of proline-directed sites and basic-residue recognition, while B56 recognizes LxxIxE motifs in substrates. (nguyen2023substrateandphosphorylation pages 3-4, verbinnen2021proteinphosphatase2a pages 1-5)
The 2024 PNAS B56δ structural study links regulation to phosphorylation-dependent activation and mitotic defects caused by disease variants, reinforcing mitotic control as an area where PP2A catalytic subunits (including PPP2CB) are functionally deployed. (wu2024b56δlongdisorderedarms pages 1-2)
Cancer-focused sources describe PP2A as a central antagonist of oncogenic pathways, with relevance to PI3K/Akt, Ras/MAPK, Wnt/β-catenin, Myc, NF-κB, and mTOR signaling; dysregulation frequently occurs via altered holoenzyme composition or inhibition by proteins such as SET/CIP2A, motivating both “reactivation” and selective inhibition strategies. (sarais2025targetingpp2ain pages 1-3, peris2023regulationandrole pages 10-11)
Several ongoing/completed clinical trials use LB-100, a PP2A inhibitor, reflecting translational interest in PP2A modulation:
These studies are not PPP2CB-selective (they target PP2A more broadly), but they demonstrate real-world targeting of the PP2A catalytic machinery to reshape phosphorylation states in tumors—directly relevant to the translational landscape of PPP2CB as a catalytic subunit. (NCT04560972 chunk 1, NCT06012734 chunk 1)
A 2023 PP2A-B56 cancer review describes clinically motivated “reactivation” approaches, including FTY720 (fingolimod) binding SET to indirectly reactivate PP2A, while noting cardiotoxicity limits and motivating development of analogs (e.g., CM-1231) and other SET-targeting agents (e.g., OSU-2S, OP449). (peris2023regulationandrole pages 10-11)
Across recent authoritative reviews, a consistent expert-level interpretation emerges:
Key quantitative results are compiled in the artifacts below.
| Topic | Statement / Mechanism | Key Quantitative Details | Key Sources | Citation ID |
|---|---|---|---|---|
| Identity | UniProt P62714 corresponds to the human PP2A catalytic subunit beta isoform (PPP2CB). | Encoded by PPP2CB gene; ~97% sequence identity to alpha isoform (PPP2CA). | Cohen 2010 ArXiv DOI; Goguet-Rubio 2020 Biomolecules DOI | (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3, cohen2010phosphatasefamiliesdephosphorylating pages 5-6) |
| Holoenzyme Composition | Heterotrimeric complex: Scaffold (A) + Catalytic (C) + Regulatory (B) subunit. | Combinatorial assembly of 2 C, 2 A, and ~15 B genes yields >70–90 distinct holoenzymes. | Nasa 2020 Biochem Soc Trans DOI; Cohen 2010 | (nasa2020effectsofcarboxylterminal pages 1-3, cohen2010phosphatasefamiliesdephosphorylating pages 7-8) |
| Catalytic Mechanism | Bimetallic (M1/M2) center activates water (bridging hydroxide) for nucleophilic attack on phosphorus. Arg89 stabilizes transition state. | Activation barrier: +15.5 kcal/mol (bidentate Arg89) vs +18.8 kcal/mol (sequestered). | Salter 2023 Front Cell Dev Biol DOI; Kokot 2022 J Cell Sci DOI | (salter2023quantumbasedmodelingimplies pages 1-2, salter2023quantumbasedmodelingimplies pages 2-3, kokot2022emerginginsightsinto pages 1-2) |
| Regulation (Methylation) | Reversible methylation of C-terminal Leu309 controls B-subunit binding; catalyzed by LCMT1, removed by PME1. | >90% methylation in NIH3T3 cells; ~74% in transformed HEK cells. | Nasa 2020 Biochem Soc Trans DOI; Goguet-Rubio 2020 | (nasa2020effectsofcarboxylterminal pages 1-3, goguetrubio2020pp2ab55holoenzymeregulation pages 1-3) |
| Biogenesis Factors | PTPA activates latent phosphatase activity (tyrosyl to seryl/threonyl) and enables methylation; alpha4 protects monomeric C. | PTPA is required for proper active site metal geometry (Mg2+/Mn2+). | Goguet-Rubio 2020 Biomolecules; Cohen 2010 | (goguetrubio2020pp2ab55holoenzymeregulation pages 1-3, cohen2010phosphatasefamiliesdephosphorylating pages 8-9) |
| Substrate Selection | Dictated by B-subunits. B55 targets basic-rich motifs and SLiMs; B56 shows distinct basophilic preferences. | B55α binds SLiM [RK]Vxx[VI]R via acidic surface; dephosphorylates >300 substrates (e.g., p53, c-MYC). |
Kokot 2022 J Cell Sci; Sarais 2025 J Exp Clin Cancer Res DOI | (kokot2022emerginginsightsinto pages 6-7, sarais2025targetingpp2ain pages 1-3) |
| Disease Association | PPP2CB identified as a plasma protein associated with celiac disease pathological grading. | Selected by machine learning as 1 of 4 key features (AUC ~0.57 in one cohort). | Li 2024 Sci Rep DOI | (li2024proteomicanalysisof pages 6-8, li2024proteomicanalysisof pages 1-2) |
Table: Summary of evidence-backed facts regarding the identity, enzymatic mechanism, regulation, and functional roles of the PPP2CB-encoded beta isoform of PP2A.
| Item | Metric | Value | Context/notes | Source (author year) | URL | Citation ID |
|---|---|---|---|---|---|---|
| PP2A–B56 cancer review | Fraction of cellular Ser/Thr phosphatase activity | 50–70% | >80 distinct heterotrimeric PP2A holoenzymes described | Peris 2023 | https://doi.org/10.1016/j.bbcan.2023.188953 | (peris2023regulationandrole pages 1-2) |
| LCMT1 methylation stoichiometry | PP2A-C Leu309 methylation | >90% (NIH3T3); ~74% (transformed HEK) | Methylation by LCMT1; demethylation by PME1; acts on AC dimer to bias B-subunit binding | Nasa 2020 | https://doi.org/10.1042/bst20200177 | (nasa2020effectsofcarboxylterminal pages 1-3) |
| B56δ cryo-EM interface | Autoinhibitory interface length | >190 Å | B56δ disordered arms contact holoenzyme core; allosteric network; Jordan’s syndrome mutations | Wu 2024 | https://doi.org/10.1073/pnas.2310727120 | (wu2024b56δlongdisorderedarms pages 1-2) |
| PP2A catalytic mechanism | Activation barrier with Arg89 vs sequestered | 15.5 vs 18.8 kcal/mol | Bidentate Arg89–phosphate binding lowers barrier in QM models | Salter 2023 | https://doi.org/10.3389/fcell.2023.1141804 | (salter2023quantumbasedmodelingimplies pages 1-2) |
| PPP2CA substrate mapping | Proteins with increased phosphorylation after PPP2CA degradation | 2,204 proteins | dTAG PPP2CA in HEK293; pSP/pTP motif enrichment | Brewer 2024 | https://doi.org/10.1016/j.isci.2024.109302 | (brewer2024mappingthesubstrate pages 1-2) |
| Celiac disease cohorts | Sample sizes (CeD vs controls) | 85 CeD, 94 controls | Discovery: 30 CeD plasma/19 mucosa (matched controls); Validation: 40 CeD plasma, 45 controls | Li 2024 | https://doi.org/10.1038/s41598-024-80391-5 | (li2024proteomicanalysisof pages 9-10) |
| PPP2CB AUC in CeD | ROC AUC for PPP2CB | 0.5661 (95% CI 0.4225–0.7097), P>0.05 | PPP2CB among 4 ML-selected plasma features associated with Marsh grading | Li 2024 | https://doi.org/10.1038/s41598-024-80391-5 | (li2024proteomicanalysisof pages 6-8) |
| LB-100 in recurrent glioblastoma (NCT03027388) | Phase/status/enrollment | Phase II; Completed; n=7 | LB-100 2.33 mg/m^2 IV 2–4 h pre-surgery; PK/PD endpoints | ClinicalTrials.gov 2019 | https://clinicaltrials.gov/study/NCT03027388 | (NCT03027388 chunk 1, NCT03027388 chunk 2) |
| LB-100 + chemo + atezolizumab in ES-SCLC (NCT04560972) | Phase/status/enrollment | Phase Ib; Active, not recruiting; n=3 | LB-100 IV 15 min days 1 & 3; 21-day cycles with carboplatin/etoposide/atezolizumab; RP2D/DLT primary | ClinicalTrials.gov 2021 | https://clinicaltrials.gov/study/NCT04560972 | (NCT04560972 chunk 1) |
| LB-100 + atezolizumab in MSS mCRC (NCT06012734) | Phase/status/enrollment | Phase Ib; Recruiting; target n=37 | LB-100 days 1 & 3; atezolizumab 1200 mg day 1; 21-day cycles; PD hyperphosphorylation biomarker | ClinicalTrials.gov 2024 | https://clinicaltrials.gov/study/NCT06012734 | (NCT06012734 chunk 1, NCT06012734 chunk 2) |
Table: This table compiles recent quantitative findings and implementations relevant to PPP2CB/PP2A, including structural metrics, enzymatic barriers, substrate-mapping counts, cohort sizes and AUCs, and details from active/complete clinical trials targeting PP2A. It provides traceable values and contexts to support functional annotation and translational relevance.
PPP2CB (PP2Acβ; UniProt P62714) is a metal-dependent serine/threonine phosphoprotein phosphatase catalytic subunit that functions predominantly as part of heterotrimeric PP2A holoenzymes (A scaffold + C catalytic + B regulatory). Its effective substrate specificity and localization are governed by regulatory B subunits and by catalytic-tail post-translational regulation (notably Leu309 methylation via LCMT1/PME-1 and nearby phosphorylation). PPP2CB is described as being predominantly cytoplasmic and nuclear, consistent with roles in cytoplasmic/nuclear dephosphorylation networks in contexts where it is expressed and assembled into active PP2A complexes. Recent 2023–2024 research has sharpened mechanistic understanding via (i) a modern specificity framework (motifs + SLiMs), (ii) structural/allosteric models of B56 holoenzyme autoinhibition and disease-mutation coupling, and (iii) emerging biomarker signals in disease proteomics where PPP2CB appears as a machine-learning–selected plasma feature (currently hypothesis-generating). (baskaran2018proteinphosphatase2a pages 6-10, nasa2020effectsofcarboxylterminal pages 1-3, wu2024b56δlongdisorderedarms pages 1-2, nguyen2023substrateandphosphorylation pages 1-3, li2024proteomicanalysisof pages 6-8)
References
(cohen2010phosphatasefamiliesdephosphorylating pages 5-6): Patricia T.W. Cohen. Phosphatase families dephosphorylating serine and threonine residues in proteins. ArXiv, pages 659-675, Jan 2010. URL: https://doi.org/10.1016/b978-0-12-374145-5.00085-1, doi:10.1016/b978-0-12-374145-5.00085-1. This article has 19 citations.
(goguetrubio2020pp2ab55holoenzymeregulation pages 1-3): Perrine Goguet-Rubio, Priya Amin, Sushil Awal, Suzanne Vigneron, Sophie Charrasse, Francisca Mechali, Jean Claude Labbé, Thierry Lorca, and Anna Castro. Pp2a-b55 holoenzyme regulation and cancer. Biomolecules, 10:1586, Nov 2020. URL: https://doi.org/10.3390/biom10111586, doi:10.3390/biom10111586. This article has 27 citations.
(cohen2010phosphatasefamiliesdephosphorylating pages 8-9): Patricia T.W. Cohen. Phosphatase families dephosphorylating serine and threonine residues in proteins. ArXiv, pages 659-675, Jan 2010. URL: https://doi.org/10.1016/b978-0-12-374145-5.00085-1, doi:10.1016/b978-0-12-374145-5.00085-1. This article has 19 citations.
(kokot2022emerginginsightsinto pages 1-2): Thomas Kokot and Maja Köhn. Emerging insights into serine/threonine-specific phosphoprotein phosphatase function and selectivity. Journal of cell science, Oct 2022. URL: https://doi.org/10.1242/jcs.259618, doi:10.1242/jcs.259618. This article has 33 citations and is from a domain leading peer-reviewed journal.
(nasa2020effectsofcarboxylterminal pages 1-3): Isha Nasa and Arminja N. Kettenbach. Effects of carboxyl-terminal methylation on holoenzyme function of the pp2a subfamily. Biochemical Society transactions, 48 5:2015-2027, Oct 2020. URL: https://doi.org/10.1042/bst20200177, doi:10.1042/bst20200177. This article has 22 citations and is from a peer-reviewed journal.
(peris2023regulationandrole pages 1-2): Irene Peris, Silvia Romero-Murillo, Carmen Vicente, Goutham Narla, and Maria D. Odero. Regulation and role of the pp2a-b56 holoenzyme family in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878:188953, Sep 2023. URL: https://doi.org/10.1016/j.bbcan.2023.188953, doi:10.1016/j.bbcan.2023.188953. This article has 21 citations and is from a peer-reviewed journal.
(cohen2010phosphatasefamiliesdephosphorylating pages 7-8): Patricia T.W. Cohen. Phosphatase families dephosphorylating serine and threonine residues in proteins. ArXiv, pages 659-675, Jan 2010. URL: https://doi.org/10.1016/b978-0-12-374145-5.00085-1, doi:10.1016/b978-0-12-374145-5.00085-1. This article has 19 citations.
(salter2023quantumbasedmodelingimplies pages 1-2): E. Alan Salter, Andrzej Wierzbicki, Richard E. Honkanen, and Mark R. Swingle. Quantum-based modeling implies that bidentate arg89-substrate binding enhances serine/threonine protein phosphatase-2a(ppp2r5d/ppp2r1a/ppp2ca)-mediated dephosphorylation. Frontiers in Cell and Developmental Biology, Jun 2023. URL: https://doi.org/10.3389/fcell.2023.1141804, doi:10.3389/fcell.2023.1141804. This article has 3 citations.
(kokot2022emerginginsightsinto pages 6-7): Thomas Kokot and Maja Köhn. Emerging insights into serine/threonine-specific phosphoprotein phosphatase function and selectivity. Journal of cell science, Oct 2022. URL: https://doi.org/10.1242/jcs.259618, doi:10.1242/jcs.259618. This article has 33 citations and is from a domain leading peer-reviewed journal.
(nguyen2023substrateandphosphorylation pages 3-4): Hieu Nguyen and Arminja N. Kettenbach. Substrate and phosphorylation site selection by phosphoprotein phosphatases. Trends in Biochemical Sciences, 48:713-725, Aug 2023. URL: https://doi.org/10.1016/j.tibs.2023.04.004, doi:10.1016/j.tibs.2023.04.004. This article has 42 citations and is from a domain leading peer-reviewed journal.
(verbinnen2021proteinphosphatase2a pages 1-5): Iris Verbinnen, Pieter Vaneynde, Sara Reynhout, Lisa Lenaerts, Rita Derua, Gunnar Houge, and Veerle Janssens. Protein phosphatase 2a (pp2a) mutations in brain function, development, and neurologic disease. Biochemical Society transactions, 49:1567-1588, Jul 2021. URL: https://doi.org/10.1042/bst20201313, doi:10.1042/bst20201313. This article has 53 citations and is from a peer-reviewed journal.
(baskaran2018proteinphosphatase2a pages 6-10): Rathinasamy Baskaran and Bharath Kumar Velmurugan. Protein phosphatase 2a as therapeutic targets in various disease models. Life Sciences, 210:40–46, Oct 2018. URL: https://doi.org/10.1016/j.lfs.2018.08.063, doi:10.1016/j.lfs.2018.08.063. This article has 79 citations and is from a peer-reviewed journal.
(peris2023regulationandrole pages 2-4): Irene Peris, Silvia Romero-Murillo, Carmen Vicente, Goutham Narla, and Maria D. Odero. Regulation and role of the pp2a-b56 holoenzyme family in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878:188953, Sep 2023. URL: https://doi.org/10.1016/j.bbcan.2023.188953, doi:10.1016/j.bbcan.2023.188953. This article has 21 citations and is from a peer-reviewed journal.
(wu2024b56δlongdisorderedarms pages 1-2): Cheng-Guo Wu, Vijaya K. Balakrishnan, Ronald A. Merrill, Pankaj S. Parihar, Kirill Konovolov, Yu-Chia Chen, Zhen Xu, Hui Wei, Ramya Sundaresan, Qiang Cui, Brian E. Wadzinski, Mark R. Swingle, Alla Musiyenko, Wendy K. Chung, Richard E. Honkanen, Aussie Suzuki, Xuhui Huang, Stefan Strack, and Yongna Xing. B56δ long-disordered arms form a dynamic pp2a regulation interface coupled with global allostery and jordan’s syndrome mutations. Proceedings of the National Academy of Sciences of the United States of America, Dec 2024. URL: https://doi.org/10.1073/pnas.2310727120, doi:10.1073/pnas.2310727120. This article has 22 citations and is from a highest quality peer-reviewed journal.
(nguyen2023substrateandphosphorylation pages 1-3): Hieu Nguyen and Arminja N. Kettenbach. Substrate and phosphorylation site selection by phosphoprotein phosphatases. Trends in Biochemical Sciences, 48:713-725, Aug 2023. URL: https://doi.org/10.1016/j.tibs.2023.04.004, doi:10.1016/j.tibs.2023.04.004. This article has 42 citations and is from a domain leading peer-reviewed journal.
(li2024proteomicanalysisof pages 6-8): Na Li, Ayinuer Maimaitireyimu, Tian Shi, Yan Feng, Weidong Liu, Shenglong Xue, and Feng Gao. Proteomic analysis of plasma and duodenal tissue in celiac disease patients reveals potential noninvasive diagnostic biomarkers. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-80391-5, doi:10.1038/s41598-024-80391-5. This article has 5 citations and is from a peer-reviewed journal.
(li2024proteomicanalysisof pages 9-10): Na Li, Ayinuer Maimaitireyimu, Tian Shi, Yan Feng, Weidong Liu, Shenglong Xue, and Feng Gao. Proteomic analysis of plasma and duodenal tissue in celiac disease patients reveals potential noninvasive diagnostic biomarkers. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-80391-5, doi:10.1038/s41598-024-80391-5. This article has 5 citations and is from a peer-reviewed journal.
(sarais2025targetingpp2ain pages 1-3): Fabio Sarais, Finja Krempien, Caroline Koehn, Lara Brewing, Carl Friedrich Classen, Michael Walter, and Olia Shokraie. Targeting pp2a in cancer: an underrated option. Journal of Experimental & Clinical Cancer Research, Oct 2025. URL: https://doi.org/10.1186/s13046-025-03560-y, doi:10.1186/s13046-025-03560-y. This article has 1 citations and is from a domain leading peer-reviewed journal.
(peris2023regulationandrole pages 10-11): Irene Peris, Silvia Romero-Murillo, Carmen Vicente, Goutham Narla, and Maria D. Odero. Regulation and role of the pp2a-b56 holoenzyme family in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878:188953, Sep 2023. URL: https://doi.org/10.1016/j.bbcan.2023.188953, doi:10.1016/j.bbcan.2023.188953. This article has 21 citations and is from a peer-reviewed journal.
(NCT03027388 chunk 1): Eric Burton. Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma. National Cancer Institute (NCI). 2019. ClinicalTrials.gov Identifier: NCT03027388
(NCT03027388 chunk 2): Eric Burton. Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma. National Cancer Institute (NCI). 2019. ClinicalTrials.gov Identifier: NCT03027388
(NCT04560972 chunk 1): LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer. City of Hope Medical Center. 2021. ClinicalTrials.gov Identifier: NCT04560972
(NCT06012734 chunk 1): LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients. The Netherlands Cancer Institute. 2024. ClinicalTrials.gov Identifier: NCT06012734
(NCT06012734 chunk 2): LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients. The Netherlands Cancer Institute. 2024. ClinicalTrials.gov Identifier: NCT06012734
(salter2023quantumbasedmodelingimplies pages 2-3): E. Alan Salter, Andrzej Wierzbicki, Richard E. Honkanen, and Mark R. Swingle. Quantum-based modeling implies that bidentate arg89-substrate binding enhances serine/threonine protein phosphatase-2a(ppp2r5d/ppp2r1a/ppp2ca)-mediated dephosphorylation. Frontiers in Cell and Developmental Biology, Jun 2023. URL: https://doi.org/10.3389/fcell.2023.1141804, doi:10.3389/fcell.2023.1141804. This article has 3 citations.
(li2024proteomicanalysisof pages 1-2): Na Li, Ayinuer Maimaitireyimu, Tian Shi, Yan Feng, Weidong Liu, Shenglong Xue, and Feng Gao. Proteomic analysis of plasma and duodenal tissue in celiac disease patients reveals potential noninvasive diagnostic biomarkers. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-80391-5, doi:10.1038/s41598-024-80391-5. This article has 5 citations and is from a peer-reviewed journal.
(brewer2024mappingthesubstrate pages 1-2): Abigail Brewer, Gajanan Sathe, Billie E. Pflug, Thomas J. Macartney, and Gopal P. Sapkota. Mapping the substrate landscape of protein phosphatase 2a catalytic subunit ppp2ca. iScience, Sep 2024. URL: https://doi.org/10.1016/j.isci.2024.109302, doi:10.1016/j.isci.2024.109302. This article has 17 citations and is from a peer-reviewed journal.
PPP2CB (UniProt P62714) encodes the catalytic subunit beta isoform of protein phosphatase 2A (PP2A-beta, PP2Acbeta). It is the minor catalytic isoform of PP2A, with PPP2CA being the major isoform (~10x more abundant in most tissues). The two share ~97% sequence identity [deep-research-falcon, goguetrubio2020, "~97% sequence similarity/identity reported in multiple authoritative reviews"].
PPP2CB is a metal-dependent serine/threonine phosphoprotein phosphatase (EC 3.1.3.16). It uses a bimetallic Mn2+ active site to hydrolyze phospho-serine and phospho-threonine bonds on protein substrates [PMID:10318862, deep-research-falcon].
The protein functions as the catalytic subunit of the heterotrimeric PP2A holoenzyme complex, consisting of:
- A (scaffold) subunit (PPP2R1A or PPP2R1B)
- C (catalytic) subunit (PPP2CA or PPP2CB)
- B (regulatory) subunit (multiple families: B/B55, B'/B56, B'', B''')
Regulatory B subunits determine substrate specificity and subcellular localization. Combinatorial assembly yields >70-90 distinct PP2A holoenzymes [deep-research-falcon, nasa2020].
PPP2CB is predominantly cytoplasmic and nuclear [deep-research-falcon, baskaran2018, "Cbeta (PPP2CB) is predominantly cytoplasmic and nuclear"]. During prometaphase, localizes to centromeres; during mitosis, found at spindle poles [UniProt subcellular location, PMID:16541025].
PPP2CB is part of the STRIPAK complex [PMID:18782753, "STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated protein Mob3, the novel proteins STRIP1 and STRIP2...PDCD10...and members of the germinal center kinase III family of Ste20 kinases"].
PMID:28159925 shows PPP2CB knockdown in MSCs increases RELA/p65 levels and, in combination with TNFalpha, enhances IL-6, CCL2, and CCL5 transcription. PPP2CB is a direct target of miR-1246. This supports roles in negative regulation of NF-kappaB and TNF-mediated signaling, but the effects are context-dependent (require TNFalpha co-stimulation for pro-inflammatory cytokine changes).
PP2A is the major tau phosphatase in human brain, accounting for ~71% of tau phosphatase activity PMID:16262633. PP2A activity negatively correlates with tau phosphorylation. This supports annotations related to tau binding and neurofibrillary tangle regulation, though these studies used PP2A broadly (not PPP2CB-specific).
id: P62714
gene_symbol: PPP2CB
product_type: PROTEIN
status: IN_PROGRESS
taxon:
id: NCBITaxon:9606
label: Homo sapiens
description: >-
PPP2CB encodes the beta isoform of the catalytic subunit of protein phosphatase
2A (PP2A), a major serine/threonine phosphatase (EC 3.1.3.16). PP2Acbeta is the
minor catalytic isoform (~97% identical to the alpha isoform PPP2CA, which is ~10x
more abundant). The catalytic subunit uses a bimetallic Mn2+ active site to
dephosphorylate phosphoserine and phosphothreonine residues on protein substrates.
PP2A functions as a heterotrimeric holoenzyme consisting of a scaffold A subunit,
catalytic C subunit, and one of many regulatory B subunits that confer substrate
specificity and subcellular localization. Combinatorial assembly of subunit
isoforms generates >70 distinct PP2A holoenzymes. PP2Acbeta is predominantly
cytoplasmic and nuclear, and is also a component of the STRIPAK complex.
C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1) is a key regulatory
mechanism controlling B subunit selection and holoenzyme assembly. PP2A opposes
kinase signaling in numerous pathways including cell cycle, Wnt/beta-catenin,
Ras/MAPK, NF-kappaB, and PI3K/Akt, and is a major regulator of tau
phosphorylation in brain.
existing_annotations:
- term:
id: GO:0004722
label: protein serine/threonine phosphatase activity
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
PPP2CB is a well-established serine/threonine phosphoprotein phosphatase.
This is the core molecular function of the protein, supported by extensive
biochemical evidence and phylogenetic analysis across eukaryotes. The IBA
annotation is well supported by broad phylogenetic conservation.
action: ACCEPT
reason: >-
This is the defining molecular function of PPP2CB. The protein catalyzes
dephosphorylation of phosphoserine and phosphothreonine residues using a
bimetallic active site. Supported by UniProt EC 3.1.3.16 assignment, deep
research review, and phylogenetic inference.
supported_by:
- reference_id: PMID:8206937
supporting_text: "Methylation of PP2Ac subunit, in vitro, increases its activity
toward both phosphorylase a and a phosphopeptide."
- reference_id: PMID:2849765
supporting_text: "The nucleotide sequence of the cDNA encoding the human lung
protein phosphatase 2A beta catalytic subunit."
- term:
id: GO:0000278
label: mitotic cell cycle
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
PP2A holoenzymes (with B55 and B56 regulatory subunits) play essential
roles in mitotic cell cycle regulation, opposing CDK-mediated
phosphorylation during cell cycle transitions. The IBA annotation is
phylogenetically well-supported.
action: ACCEPT
reason: >-
PP2A is a central regulator of mitotic cell cycle progression. PP2A-B55
and PP2A-B56 are required for mitotic exit, opposing CDK substrates.
UniProt lists roles in kinetochore/centromere and spindle pole
localization during mitosis. The phylogenetic inference is appropriate.
supported_by:
- reference_id: PMID:27880917
supporting_text: "complementary affinity purification and proximity-based interaction
proteomics approaches to generate a physical interactome for 140 human proteins
harboring phosphatase catalytic domains"
- term:
id: GO:0005829
label: cytosol
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
PPP2CB is active in the cytosol, consistent with its role as a major
cytoplasmic phosphatase. The IBA annotation is well supported by both
phylogenetic evidence and experimental localization data.
action: ACCEPT
reason: >-
Cytosolic localization of PP2A catalytic subunits is well established.
UniProt lists cytoplasm as a subcellular location for PPP2CB. Reactome
pathways also place PPP2CB in cytosol for various signaling events.
supported_by:
- reference_id: PMID:16541025
supporting_text: "PP2A colocalizes with shugoshin at centromeres and is required
for centromeric protection."
- term:
id: GO:0000775
label: chromosome, centromeric region
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
IEA annotation derived from UniProt subcellular location vocabulary.
UniProt cites PMID:16541025 (Kitajima et al. 2006) showing PP2A localizes
to centromeres in prometaphase cells via interaction with SGO1.
action: ACCEPT
reason: >-
The localization is experimentally supported. UniProt states:
"In prometaphase cells, but not in anaphase cells, localizes at
centromeres." This is based on PMID:16541025 which directly demonstrated
PP2A-SGO1 interaction at centromeres.
supported_by:
- reference_id: PMID:16541025
supporting_text: "a specific subtype of serine/threonine protein phosphatase
2A (PP2A) associating with human shugoshin. PP2A colocalizes with shugoshin
at centromeres"
- term:
id: GO:0000922
label: spindle pole
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
IEA from UniProt subcellular location. UniProt states PP2A is found at
spindle poles during mitosis, based on PMID:16541025.
action: ACCEPT
reason: >-
Spindle pole localization during mitosis is documented in UniProt
subcellular location, which cites PMID:16541025. Consistent with PP2A
role in mitotic regulation.
supported_by:
- reference_id: PMID:16541025
supporting_text: "crucial--particularly at centromeres--for proper chromosome
segregation in mitosis and meiosis"
- term:
id: GO:0004722
label: protein serine/threonine phosphatase activity
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
Combined automated annotation from multiple IEA methods confirming
protein serine/threonine phosphatase activity. Redundant with IBA and
TAS annotations for the same term but independently valid.
action: ACCEPT
reason: >-
Correct core function. This IEA annotation is consistent with the more
authoritative IBA and TAS annotations for the same GO term.
- term:
id: GO:0005634
label: nucleus
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
IEA from UniProt subcellular location. PPP2CB has been experimentally
shown to localize to the nucleus, consistent with its role in nuclear
phosphatase activity and its description as predominantly cytoplasmic
and nuclear.
action: ACCEPT
reason: >-
Nuclear localization is well supported. UniProt cites PMID:16541025 and
also states PPP2CB is nucleoplasmic (IDA from HPA). Deep research
confirms PPP2CB is predominantly cytoplasmic and nuclear.
supported_by:
- reference_id: PMID:16541025
supporting_text: "PP2A colocalizes with shugoshin at centromeres and is required
for centromeric protection"
- term:
id: GO:0005737
label: cytoplasm
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
IEA annotation for cytoplasm localization. Broader than cytosol but still
correct. PPP2CB is well established as a cytoplasmic protein.
action: ACCEPT
reason: >-
Cytoplasm is a broader parent term of cytosol. PPP2CB is well established
in both cytosol and cytoplasm. Consistent with IBA cytosol annotation and
UniProt subcellular location.
- term:
id: GO:0016787
label: hydrolase activity
evidence_type: IEA
original_reference_id: GO_REF:0000002
review:
summary: >-
IEA from InterPro domain mapping. Hydrolase activity is correct but too
general for a protein whose specific phosphatase activity is well
characterized. The more specific GO:0004722 annotations exist.
action: ACCEPT
reason: >-
While very broad, hydrolase activity is technically correct as a parent
of phosphatase activity. The more specific GO:0004722 annotations also
exist. This IEA is acceptable as a domain-based annotation even though
more informative terms are present.
- term:
id: GO:0090443
label: FAR/SIN/STRIPAK complex
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
IEA from ARBA machine learning model predicting STRIPAK complex
membership. This is consistent with experimental evidence from
PMID:18782753 (IDA annotation also present).
action: ACCEPT
reason: >-
Correct annotation. PPP2CB was experimentally identified as part of the
STRIPAK complex in PMID:18782753, and a separate IDA annotation exists.
This IEA is redundant but valid.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:10698523
review:
summary: >-
IPI based on interaction with AXIN2 (Q9Y2T1). The study showed PP2A
complexed with Axin dephosphorylates APC in Wnt signaling. The
interaction is functionally meaningful (Wnt pathway regulation) but
annotated as generic protein binding.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. The interaction with AXIN2 reflects
PP2A recruitment to the beta-catenin destruction complex. A more
informative annotation would capture the specific functional context
(e.g., phosphatase activity in the Wnt pathway), but that is a BP
annotation, not MF. The IPI evidence does not support a more specific
MF term than protein binding.
supported_by:
- reference_id: PMID:10698523
supporting_text: "the heterodimeric form of protein phosphatase 2A (PP2A) directly
bound to Axin, and PP2A complexed with Axin dephosphorylated APC phosphorylated
by GSK-3beta"
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:16085932
review:
summary: >-
IPI based on interaction with TIPRL (O75663). The study characterized a
PP4 complex involved in cisplatin sensitivity. TIPRL is a known PP2A
interactor and phosphatase regulator. Annotated as generic protein binding.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. TIPRL interaction with PP2A catalytic
subunits is part of the phosphatase regulatory network, but the GO
term does not capture the functional significance. The primary study
focused on PP4, not PP2A.
supported_by:
- reference_id: PMID:16085932
supporting_text: "Using a combination of tandem affinity purification tagging
and mass spectrometry, we characterized a novel, evolutionarily conserved
protein phosphatase 4 (PP4)-containing complex"
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:18782753
review:
summary: >-
IPI for interaction with IGBP1/alpha4 (P78318) and STRIP1 (Q5VSL9) from
the PP2A high-density interaction network study that defined the STRIPAK
complex. These are well-established PP2A complex components.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. Both IGBP1 and STRIP1 are functional
PP2A-associated proteins. The interactions are better captured by the
STRIPAK complex (GO:0090443) and PP2A complex (GO:0000159) annotations.
supported_by:
- reference_id: PMID:18782753
supporting_text: "STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding
(PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated
protein Mob3, the novel proteins STRIP1 and STRIP2"
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:19156129
review:
summary: >-
IPI for interaction with IGBP1 (P78318) from an integrated PP2A
interaction proteomics workflow. This is a well-characterized PP2A
regulatory interaction.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. IGBP1/alpha4 is a known PP2A
chaperone/regulatory protein. Better captured by complex membership
annotations.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:20969868
review:
summary: >-
IPI for interaction with FHL1B (Q13642-2). Study demonstrated FHL1B
specifically interacts with PP2A catalytic beta subunit (PPP2CB) by
yeast two-hybrid and co-immunoprecipitation, suggesting a novel
cell-cycle regulatory pathway.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. The FHL1B interaction is PPP2CB-specific
(not shown for PPP2CA) and linked to cell cycle regulation, which is
interesting but the GO term does not capture this specificity.
supported_by:
- reference_id: PMID:20969868
supporting_text: "FHL1B was demonstrated to interact with the beta catalytic
subunit (Cbeta) of a type 2A protein phosphatase (PP2A) by yeast two-hybrid
screening"
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:25531779
review:
summary: >-
IPI for interaction with STRIP1 (Q5VSL9) from STRIPAK complex study on
cancer cell migration and metastasis. High-throughput proteomics study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. STRIP1 interaction is part of STRIPAK
complex, better captured by GO:0090443.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:26496610
review:
summary: >-
IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from
quantitative human interactome study. Large-scale proteomics.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. Both are known PP2A complex components.
High-throughput study; interactions better captured by complex annotations.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:27880917
review:
summary: >-
IPI for interactions with TIPRL (O75663) and IGBP1 (P78318) from
comprehensive phosphatase interactome profiling. Study identified
diverse mitotic regulators among phosphatase interactors.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. Both TIPRL and IGBP1 are established
PP2A regulators. The study provides valuable interactome data but
protein binding does not convey functional information.
supported_by:
- reference_id: PMID:27880917
supporting_text: "complementary affinity purification and proximity-based interaction
proteomics approaches to generate a physical interactome for 140 human proteins
harboring phosphatase catalytic domains"
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:28514442
review:
summary: >-
IPI for interaction with STRIP1 (Q5VSL9) from architecture of the human
interactome study. Large-scale proteomics.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. STRIP1 is a STRIPAK component.
High-throughput study.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:32814053
review:
summary: >-
IPI for interaction with FMR1/FMRP (Q06787-7) from neurodegenerative
disease interactome mapping study. The interaction was identified by
mass spectrometry in a large-scale screen.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. The FMR1 interaction is from a
high-throughput screen and the functional significance for PPP2CB is
unclear. PP2A may dephosphorylate FMRP but this is not demonstrated
in this study.
supported_by:
- reference_id: PMID:32814053
supporting_text: "Interactome Mapping Provides a Network of Neurodegenerative
Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains"
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:33961781
review:
summary: >-
IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from dual
proteome-scale cell-specific interactome study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. Both are established PP2A complex
members. High-throughput study.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:35271311
review:
summary: >-
IPI for interactions with IGBP1 (P78318) and STRIP1 (Q5VSL9) from the
OpenCell endogenous tagging study. Large-scale proteomics.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. Both are known PP2A/STRIPAK complex
members. High-throughput study.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:9647778
review:
summary: >-
IPI for interaction with IGBP1/alpha4 (P78318). Study demonstrated
alpha4 associates constitutively with both PP2A catalytic isoforms,
PP4C, and PP6C. This is a well-established functional interaction
where alpha4 serves as a chaperone protecting monomeric PP2A C subunit.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. The alpha4-PP2Ac interaction is
functionally important for PP2A biogenesis and stability. However,
the GO term protein binding does not capture this functional role.
supported_by:
- reference_id: PMID:9647778
supporting_text: "alpha 4, a previously identified phosphoprotein, associates
constitutively with the catalytic subunits of PP4, PP6, and both isoforms
of PP2A"
- term:
id: GO:0000159
label: protein phosphatase type 2A complex
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA from Ensembl Compara transfer from mouse PPP2CB. PPP2CB is a
catalytic subunit of the PP2A holoenzyme complex, which is its primary
functional context.
action: ACCEPT
reason: >-
Core annotation. PPP2CB is a defining component of the PP2A
holoenzyme complex. Strongly supported by extensive biochemical and
structural evidence. Also has a TAS annotation (PMID:8206937).
- term:
id: GO:0004721
label: phosphoprotein phosphatase activity
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA from Ensembl Compara. Phosphoprotein phosphatase activity is a
parent term of protein serine/threonine phosphatase activity
(GO:0004722). Correct but less specific than GO:0004722.
action: ACCEPT
reason: >-
Technically correct as PPP2CB does have phosphoprotein phosphatase
activity. More specific GO:0004722 annotations are also present. This
broader IEA is acceptable.
- term:
id: GO:0010288
label: response to lead ion
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA transferred from rat PPP2CB (P62716) via Ensembl Compara. Based on
rat studies showing PP2A activity is affected by lead exposure. Duplicate
with ISS annotation below.
action: KEEP_AS_NON_CORE
reason: >-
Response to lead ion is not a core function of PPP2CB. Lead ions can
inhibit PP2A activity (as they affect many metalloenzymes), but this is
a toxicological response rather than a primary biological function.
Keeping as non-core given the supporting evidence from rat studies.
- term:
id: GO:0031113
label: regulation of microtubule polymerization
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA transferred from rat PPP2CB via Ensembl Compara. PP2A regulates
microtubule dynamics through dephosphorylation of MAPs (MAP1b, MAP2, tau).
This is consistent with PP2A's role in cytoskeletal regulation.
action: KEEP_AS_NON_CORE
reason: >-
PP2A regulates microtubule polymerization indirectly by dephosphorylating
microtubule-associated proteins. PMID:10640627 showed PP2A regulates
MAP1b and MAP2 phosphorylation and their microtubule binding activity.
This is a downstream consequence of PP2A phosphatase activity rather
than a core function of PPP2CB specifically.
supported_by:
- reference_id: PMID:10640627
supporting_text: "The inhibition of PP2A, and to a lesser extent of PP2B, was
found to induce an increased phosphorylation of MAP1b and inhibit its microtubule
binding activity"
- term:
id: GO:0044325
label: transmembrane transporter binding
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA transferred from rat PPP2CB via Ensembl Compara. PP2A interacts
with various membrane transporters and channels to regulate their
phosphorylation state. Limited direct evidence for PPP2CB specifically.
action: UNDECIDED
reason: >-
The evidence for transmembrane transporter binding is based on
computational transfer from rat. While PP2A can regulate transporter
phosphorylation, the specificity and directness of a binding interaction
is not well documented for PPP2CB specifically. Unable to verify the
original rat experimental evidence.
- term:
id: GO:0046580
label: negative regulation of Ras protein signal transduction
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA transferred from rat PPP2CB via Ensembl Compara. PP2A
dephosphorylates components of the Ras/MAPK pathway, acting as a
negative regulator. This is well established for PP2A holoenzymes
generally.
action: KEEP_AS_NON_CORE
reason: >-
PP2A is well established as a negative regulator of Ras/MAPK signaling,
including dephosphorylation of RAF and ERK pathway components. However,
this represents one of many PP2A-regulated pathways and is driven by
specific B subunit combinations rather than PPP2CB specifically. Deep
research review confirms PP2A antagonizes Ras/MAPK signaling.
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: IDA
original_reference_id: GO_REF:0000052
review:
summary: >-
IDA from HPA immunofluorescence data. PPP2CB was detected in
nucleoplasm by immunofluorescence. Consistent with UniProt subcellular
location annotation showing nuclear localization.
action: ACCEPT
reason: >-
Nucleoplasm localization is experimentally supported by HPA
immunofluorescence and consistent with UniProt subcellular location
showing nuclear localization (PMID:16541025). Deep research also
describes PPP2CB as predominantly cytoplasmic and nuclear.
- term:
id: GO:1902996
label: regulation of neurofibrillary tangle assembly
evidence_type: TAS
original_reference_id: PMID:16262633
review:
summary: >-
TAS annotation based on a study showing PP2A is the major tau
phosphatase in human brain (~71% of total tau phosphatase activity),
and PP2A activity is decreased in AD brain, correlating with tau
hyperphosphorylation and neurofibrillary tangle formation.
action: KEEP_AS_NON_CORE
reason: >-
While PP2A is clearly the major tau phosphatase, this represents a
downstream physiological consequence of PP2A phosphatase activity in
brain rather than a core function of PPP2CB. Additionally, the study
used PP2A generally (likely predominantly PPP2CA given its higher
expression in brain). The annotation is not wrong but represents a
non-core, tissue-specific function.
supported_by:
- reference_id: PMID:16262633
supporting_text: "PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately
11%, approximately 10% and approximately 7%, respectively, of the total tau
phosphatase activity of human brain"
- term:
id: GO:0043124
label: negative regulation of canonical NF-kappaB signal transduction
evidence_type: IGI
original_reference_id: PMID:28159925
review:
summary: >-
IGI annotation from a study showing miR-1246 directly targets PPP2CB,
and PPP2CB knockdown increases p65/NF-kappaB levels in MSCs. The IGI
evidence is based on interaction with RELA/p65 (Q04206).
action: KEEP_AS_NON_CORE
reason: >-
The study provides evidence that PPP2CB negatively regulates NF-kappaB
signaling, but in a specific cellular context (MSCs in tumor
microenvironment). PPP2CB knockdown increased RELA expression and total
p65 levels but did not directly increase phospho-p65. The effect on
pro-inflammatory cytokines required additional TNFalpha stimulation.
This represents a non-core, context-dependent function.
supported_by:
- reference_id: PMID:28159925
supporting_text: "Knock-down of PPP2CB significantly increased RELA expression"
- reference_id: PMID:28159925
supporting_text: "knock-down of either PRKAR1A or PPP2CB led to a significant
up-regulation of total p65 in MSCs whereas phosphorylation of p65 at Ser536
remained unaffected"
- term:
id: GO:0090443
label: FAR/SIN/STRIPAK complex
evidence_type: IDA
original_reference_id: PMID:18782753
review:
summary: >-
IDA annotation showing PPP2CB is part of the STRIPAK complex, based
on iterative affinity purification/mass spectrometry in human cells.
The study defined the STRIPAK complex and identified PPP2CB as a core
component.
action: ACCEPT
reason: >-
Well-supported experimental evidence. The study used iterative AP-MS
to identify PPP2CB in the STRIPAK complex, which contains PP2A
catalytic and scaffolding subunits, striatins, MOB4, STRIP1/2, PDCD10,
and STE20 kinases. This is a core complex for PPP2CB function.
supported_by:
- reference_id: PMID:18782753
supporting_text: "STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding
(PP2A A) subunits, the striatins (PP2A regulatory B''' subunits), the striatin-associated
protein Mob3, the novel proteins STRIP1 and STRIP2"
- term:
id: GO:0010629
label: negative regulation of gene expression
evidence_type: IGI
original_reference_id: PMID:28159925
review:
summary: >-
IGI annotation (with TNFalpha P01375) showing PPP2CB acts upstream of
negative regulation of gene expression. Based on the miR-1246/PPP2CB
study in MSCs where PPP2CB knockdown combined with TNFalpha enhanced
expression of pro-inflammatory genes.
action: MARK_AS_OVER_ANNOTATED
reason: >-
This annotation is overly broad. The study showed PPP2CB knockdown
combined with TNFalpha increases IL-6, CCL2, CCL5 transcription in
MSCs. This means PPP2CB normally negatively regulates expression of
these specific inflammatory genes, but the term "negative regulation
of gene expression" is too generic. Additionally, the qualifier is
acts_upstream_of rather than involved_in, indicating indirect effects.
supported_by:
- reference_id: PMID:28159925
supporting_text: "knock-down of PPP2CB in combination with TNFalpha stimulation
phenocopied the miR-1246-enhanced transcriptional response of IL-6"
- term:
id: GO:0010629
label: negative regulation of gene expression
evidence_type: IMP
original_reference_id: PMID:28159925
review:
summary: >-
IMP annotation showing PPP2CB is involved in negative regulation of
gene expression, based on the same miR-1246 study in MSCs.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Same concern as the IGI annotation above. The term is too broad. The
evidence shows PPP2CB normally suppresses inflammatory gene expression
in MSCs, but this is a very general biological process annotation that
does not capture specificity. The NF-kappaB annotation (GO:0043124)
is more specific and informative.
supported_by:
- reference_id: PMID:28159925
supporting_text: "knock-down of PPP2CB significantly decreased releases of IL-6
and CCL2"
- term:
id: GO:0010804
label: negative regulation of tumor necrosis factor-mediated signaling
pathway
evidence_type: IGI
original_reference_id: PMID:28159925
review:
summary: >-
IGI annotation showing PPP2CB acts upstream of negative regulation of
TNF-mediated signaling. Based on the miR-1246 study where PPP2CB
knockdown combined with TNFalpha enhances inflammatory responses.
action: KEEP_AS_NON_CORE
reason: >-
The evidence supports that PPP2CB negatively regulates TNF-mediated
signaling in MSCs. PPP2CB knockdown released negative feedback on
IL-6 transcription after TNFalpha stimulation. However, this is a
context-dependent effect in MSCs and represents a non-core function.
supported_by:
- reference_id: PMID:28159925
supporting_text: "knock-down of PPP2CB in combination with TNFalpha stimulation
phenocopied the miR-1246-enhanced transcriptional response of IL-6 in combination
with TNFalpha"
- term:
id: GO:0004722
label: protein serine/threonine phosphatase activity
evidence_type: TAS
original_reference_id: PMID:8206937
review:
summary: >-
TAS annotation from the study that demonstrated carboxyl methylation of
PP2A catalytic subunit in vivo. The paper confirms PP2Ac phosphatase
activity toward phosphorylase a and phosphopeptide substrates.
action: ACCEPT
reason: >-
Core molecular function, directly supported by the cited publication
which demonstrated PP2Ac enzymatic activity.
supported_by:
- reference_id: PMID:8206937
supporting_text: "Methylation of PP2Ac subunit, in vitro, increases its activity
toward both phosphorylase a and a phosphopeptide"
- term:
id: GO:0048156
label: tau protein binding
evidence_type: NAS
original_reference_id: PMID:28386764
review:
summary: >-
NAS annotation based on a comprehensive review of tau protein roles in
health and disease. PP2A is well established as the major tau
phosphatase, which implies physical binding to tau.
action: KEEP_AS_NON_CORE
reason: >-
PP2A does bind and dephosphorylate tau protein, but this is primarily
documented for PP2A holoenzymes in brain (likely predominantly
PPP2CA-containing). The NAS evidence from a review article is weak.
Tau binding is a substrate interaction for PP2A rather than a core
binding function. Keeping as non-core given that PP2A-tau interaction
is well established in the broader literature.
supported_by:
- reference_id: PMID:28386764
supporting_text: "Tau is well established as a microtubule-associated protein
in neurons"
- reference_id: PMID:16262633
supporting_text: "PP2A is the major tau phosphatase that regulates its phosphorylation
at multiple sites in human brain"
- term:
id: GO:0010288
label: response to lead ion
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation transferred from rat PPP2CB (P62716) by curator
judgment. PP2A activity can be affected by lead exposure, as lead
interferes with the metalloenzyme's active site.
action: KEEP_AS_NON_CORE
reason: >-
Consistent with the IEA annotation for the same term. Response to lead
ion is a toxicological response rather than a core function. The ISS
transfer from rat is appropriate given near-identical sequence.
- term:
id: GO:0004722
label: protein serine/threonine phosphatase activity
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation transferred from rat PPP2CB (P62716). Core phosphatase
activity, redundant with other annotations for the same term.
action: ACCEPT
reason: >-
Correct core function. ISS transfer from rat is fully appropriate
given near-100% sequence identity between human and rat PPP2CB.
- term:
id: GO:0004722
label: protein serine/threonine phosphatase activity
evidence_type: TAS
original_reference_id: PMID:10640627
review:
summary: >-
TAS annotation from a study on PP2A regulation of MAP1b and MAP2
phosphorylation in rat brain. Confirms PP2A serine/threonine
phosphatase activity toward neuronal substrates.
action: ACCEPT
reason: >-
Core molecular function. The study directly demonstrated PP2A
phosphatase activity toward MAP substrates.
supported_by:
- reference_id: PMID:10640627
supporting_text: "PP2A might be the major PP that participates in regulation
of the phosphorylation of MAP1b and MAP2 and their biological activities"
- term:
id: GO:0004722
label: protein serine/threonine phosphatase activity
evidence_type: TAS
original_reference_id: PMID:16262633
review:
summary: >-
TAS annotation from the tau phosphorylation study. PP2A accounts for
~71% of tau phosphatase activity in human brain.
action: ACCEPT
reason: >-
Core molecular function. The study quantitatively demonstrated PP2A
phosphatase activity toward tau.
supported_by:
- reference_id: PMID:16262633
supporting_text: "PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately
11%, approximately 10% and approximately 7%, respectively, of the total tau
phosphatase activity of human brain"
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1295599
review:
summary: >-
TAS from Reactome pathway for SPRY2 translocation to plasma membrane.
Places PPP2CB in cytosol as part of Spry regulation of FGF signaling.
action: ACCEPT
reason: >-
Cytosol localization is correct and well-supported. Reactome annotation
reflects PPP2CB involvement in SPRY2/FGF signaling regulation in the
cytosol.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1295609
review:
summary: >-
TAS from Reactome pathway for SRC phosphorylation of SPRY2. Places
PPP2CB in cytosol.
action: ACCEPT
reason: >-
Cytosol localization is correct. Redundant with other cytosol
annotations but valid from Reactome evidence.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1295613
review:
summary: >-
TAS from Reactome pathway for SPRY2-GRB2 binding. Places PPP2CB in
cytosol.
action: ACCEPT
reason: >-
Cytosol localization is correct. Redundant with other cytosol
annotations but valid.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1295622
review:
summary: >-
TAS from Reactome pathway for SPRY2-CBL binding. Places PPP2CB in
cytosol.
action: ACCEPT
reason: >-
Cytosol localization is correct. Redundant with other cytosol
annotations but valid.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1295632
review:
summary: >-
TAS from Reactome pathway for PP2A dephosphorylation of SPRY2. This
directly reflects PP2A phosphatase activity in the cytosol acting on
the SPRY2 substrate.
action: ACCEPT
reason: >-
Cytosol localization is correct and directly relevant to PP2A function.
This Reactome entry describes the actual dephosphorylation reaction
catalyzed by PP2A on SPRY2.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1549564
review:
summary: >-
TAS from Reactome pathway for PTPN11 dephosphorylation of SPRY2.
Places PPP2CB in cytosol.
action: ACCEPT
reason: >-
Cytosol localization is correct. Redundant with other cytosol
annotations.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-934559
review:
summary: >-
TAS from Reactome pathway for SPRY2 phosphorylation by MNK1. Places
PPP2CB in cytosol.
action: ACCEPT
reason: >-
Cytosol localization is correct. Redundant with other cytosol
annotations.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:21784977
review:
summary: >-
IPI for interaction with TTP/ZFP36 (P26651). The study focused on TTP
regulation of CCL3 mRNA and tissue inflammation. The interaction with
PPP2CB was likely identified as part of a broader interactome screen.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Protein binding is uninformative. The TTP-PPP2CB interaction may
reflect PP2A regulation of TTP phosphorylation (TTP activity is
regulated by phosphorylation), but the study focused on TTP-mRNA
interactions, not PP2A function.
supported_by:
- reference_id: PMID:21784977
supporting_text: "Zinc finger protein tristetraprolin (TTP) modulates macrophage
inflammatory activity by destabilizing cytokine mRNAs"
- term:
id: GO:0000159
label: protein phosphatase type 2A complex
evidence_type: TAS
original_reference_id: PMID:8206937
review:
summary: >-
TAS annotation from the carboxyl-methylation study, which demonstrated
PP2A exists as a complex with methylated catalytic subunit. The study
worked with PP2A holoenzyme from MCF7 cells.
action: ACCEPT
reason: >-
Core annotation. PPP2CB is a defining component of the PP2A complex.
The study directly worked with PP2A holoenzyme complexes.
supported_by:
- reference_id: PMID:8206937
supporting_text: "Treatment of extracts from human breast cancer (MCF7) cells
with either alkali or ethanol increased immunoreactivity of PP2Ac subunit
severalfold"
- term:
id: GO:0006470
label: protein dephosphorylation
evidence_type: TAS
original_reference_id: PMID:2849765
review:
summary: >-
TAS annotation from the original cDNA cloning paper for human PPP2CB.
The paper established PPP2CB as a phosphatase catalytic subunit.
action: ACCEPT
reason: >-
Core biological process. Protein dephosphorylation is the fundamental
reaction catalyzed by PPP2CB. This is directly supported by the
identification of PPP2CB as a PP2A catalytic subunit.
supported_by:
- reference_id: PMID:2849765
supporting_text: "The nucleotide sequence of the cDNA encoding the human lung
protein phosphatase 2A beta catalytic subunit"
- term:
id: GO:0046872
label: metal ion binding
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
PPP2CB requires two Mn2+ ions at its active site for catalytic
activity. Metal ion binding is inherent to its phosphatase mechanism.
This annotation is present in UniProt GO lines but was not in the
GOA TSV extract; adding as it appears in UniProt.
action: NEW
reason: >-
PPP2CB uses a bimetallic Mn2+ active site for catalysis. UniProt lists
multiple Mn2+ binding sites (residues 57, 59, 85, 117, 167, 241) and
includes metal ion binding as a GO annotation. This is a core aspect
of the catalytic mechanism.
supported_by:
- reference_id: PMID:10318862
supporting_text: "substitution of glutamine for either of two putative active
site histidines in the PP2A C subunit results in inactivation of PP2A"
core_functions:
- molecular_function:
id: GO:0004722
label: protein serine/threonine phosphatase activity
description: >-
PPP2CB is the beta catalytic subunit of PP2A, a major cellular Ser/Thr phosphatase
(EC 3.1.3.16). It dephosphorylates phosphoserine and phosphothreonine residues
on
protein substrates using a bimetallic Mn2+ active site. PPP2CB functions as the
catalytic engine of heterotrimeric PP2A holoenzymes (A scaffold + C catalytic
+ B
regulatory subunit). Substrate specificity is determined by the regulatory B subunit
incorporated into the holoenzyme. PPP2CB is the minor catalytic isoform (~97%
identical to PPP2CA but ~10x less abundant), and is predominantly cytoplasmic
and
nuclear. C-terminal Leu-309 methylation by LCMT1 (reversed by PME-1) regulates
holoenzyme assembly and B subunit selection.
directly_involved_in:
- id: GO:0006470
label: protein dephosphorylation
- id: GO:0000278
label: mitotic cell cycle
locations:
- id: GO:0005829
label: cytosol
- id: GO:0005654
label: nucleoplasm
in_complex:
id: GO:0000159
label: protein phosphatase type 2A complex
supported_by:
- reference_id: PMID:8206937
supporting_text: >-
Methylation of PP2Ac subunit, in vitro, increases its activity toward both
phosphorylase a and a phosphopeptide.
- reference_id: PMID:2849765
supporting_text: >-
The nucleotide sequence of the cDNA encoding the human lung protein phosphatase
2A beta catalytic subunit.
- reference_id: PMID:16262633
supporting_text: >-
PP2A accounted for approximately 71% of the total tau phosphatase activity of
human brain.
full_text_unavailable: true
- molecular_function:
id: GO:0004722
label: protein serine/threonine phosphatase activity
description: >-
PPP2CB functions as the catalytic subunit within the STRIPAK complex
(FAR/SIN/STRIPAK complex), a large signaling assembly that includes PP2A catalytic
and scaffolding subunits, striatins (B''' regulatory subunits), MOB4, STRIP1/2,
PDCD10/CCM3, and germinal center kinase III family STE20 kinases. In this context,
PPP2CB provides phosphatase activity that opposes the kinase activities within
the
complex, regulating cell migration, polarity, and cerebral cavernous malformation
signaling.
directly_involved_in:
- id: GO:0006470
label: protein dephosphorylation
locations:
- id: GO:0005829
label: cytosol
in_complex:
id: GO:0090443
label: FAR/SIN/STRIPAK complex
supported_by:
- reference_id: PMID:18782753
supporting_text: >-
STRIPAK contains the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits,
the striatins (PP2A regulatory B''' subunits), the striatin-associated protein
Mob3, the novel proteins STRIP1 and STRIP2, PDCD10, and members of the germinal
center kinase III family of Ste20 kinases.
full_text_unavailable: true
references:
- id: GO_REF:0000002
title: Gene Ontology annotation through association of InterPro records with
GO terms
findings: []
- id: GO_REF:0000024
title: Manual transfer of experimentally-verified manual GO annotation data to
orthologs by curator judgment of sequence similarity
findings: []
- id: GO_REF:0000033
title: Annotation inferences using phylogenetic trees
findings: []
- id: GO_REF:0000043
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping,
accompanied by conservative changes to GO terms applied by UniProt
findings: []
- id: GO_REF:0000044
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular
Location vocabulary mapping, accompanied by conservative changes to GO terms
applied by UniProt
findings: []
- id: GO_REF:0000052
title: Gene Ontology annotation based on curation of immunofluorescence data
findings: []
- id: GO_REF:0000107
title: Automatic transfer of experimentally verified manual GO annotation data
to orthologs using Ensembl Compara
findings: []
- id: GO_REF:0000117
title: Electronic Gene Ontology annotations created by ARBA machine learning
models
findings: []
- id: GO_REF:0000120
title: Combined Automated Annotation using Multiple IEA Methods
findings: []
- id: PMID:2849765
title: The nucleotide sequence of the cDNA encoding the human lung protein
phosphatase 2A beta catalytic subunit.
findings:
- statement: Original cDNA cloning and sequencing of human PPP2CB from lung
tissue.
- id: PMID:8206937
title: The catalytic subunit of protein phosphatase 2A is carboxyl-methylated
in vivo.
findings:
- statement: Demonstrated carboxyl-methylation of PP2Ac at Leu-309 in vivo;
methylation increases phosphatase activity.
- id: PMID:9647778
title: Alpha 4 associates with protein phosphatases 2A, 4, and 6.
findings:
- statement: Alpha4/IGBP1 constitutively associates with PP2A, PP4, and PP6
catalytic subunits.
- id: PMID:10318862
title: A protein phosphatase methylesterase (PME-1) is one of several novel
proteins stably associating with two inactive mutants of protein phosphatase
2A.
findings:
- statement: Identified PME-1 as PP2A demethylase; H59Q and H118Q mutations
inactivate PP2A catalytic activity.
- id: PMID:10640627
title: Regulation of phosphorylation of neuronal microtubule-associated
proteins MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain.
findings:
- statement: PP2A is the major phosphatase regulating MAP1b and MAP2
phosphorylation and microtubule binding activity.
- id: PMID:10698523
title: GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene
product can be modulated by beta-catenin and protein phosphatase 2A
complexed with Axin.
findings:
- statement: PP2A directly binds Axin and dephosphorylates APC phosphorylated
by GSK-3beta in Wnt signaling.
- id: PMID:16085932
title: A novel, evolutionarily conserved protein phosphatase complex involved
in cisplatin sensitivity.
findings:
- statement: Characterized PP4-containing complex; TIPRL interacts with PP2A
family catalytic subunits.
- id: PMID:16262633
title: Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the
regulation of tau phosphorylation.
findings:
- statement: PP2A accounts for ~71% of total tau phosphatase activity in human
brain; activity decreased in AD brain.
- id: PMID:16541025
title: Shugoshin collaborates with protein phosphatase 2A to protect cohesin.
findings:
- statement: PP2A localizes to centromeres in prometaphase via SGO1
interaction; also found at spindle poles during mitosis.
- id: PMID:18782753
title: A PP2A phosphatase high density interaction network identifies a novel
striatin-interacting phosphatase and kinase complex linked to the cerebral
cavernous malformation 3 (CCM3) protein.
findings:
- statement: Defined the STRIPAK complex containing PP2A catalytic/scaffolding
subunits, striatins, MOB4, STRIP1/2, PDCD10, and STE20 kinases.
- id: PMID:19156129
title: 'An integrated workflow for charting the human interaction proteome: insights
into the PP2A system.'
findings:
- statement: Mapped the PP2A interaction network including IGBP1/alpha4
binding to PP2A catalytic subunits.
- id: PMID:20969868
title: "LIM domain protein FHL1B interacts with PP2A catalytic β subunit--a novel
cell cycle regulatory pathway."
findings:
- statement: FHL1B specifically interacts with PPP2CB (not PPP2CA was tested)
by yeast two-hybrid and co-IP; linked to cell cycle regulation.
- id: PMID:21784977
title: Zinc finger protein tristetraprolin interacts with CCL3 mRNA and
regulates tissue inflammation.
findings:
- statement: TTP/ZFP36 interacts with PPP2CB; TTP modulates inflammatory
cytokine mRNA stability.
- id: PMID:25531779
title: STRIPAK components determine mode of cancer cell migration and
metastasis.
findings:
- statement: STRIPAK complex components including STRIP1 interact with PP2A
catalytic subunits in cancer cell migration.
- id: PMID:26496610
title: A human interactome in three quantitative dimensions organized by
stoichiometries and abundances.
findings:
- statement: High-throughput interactome study confirming IGBP1 and STRIP1
interactions with PPP2CB.
- id: PMID:27880917
title: Phenotypic and Interaction Profiling of the Human Phosphatases
Identifies Diverse Mitotic Regulators.
findings:
- statement: Comprehensive phosphatase interactome profiling; PPP2CB interacts
with TIPRL and IGBP1.
- id: PMID:28159925
title: miRNA-1246 induces pro-inflammatory responses in mesenchymal
stem/stromal cells by regulating PKA and PP2A.
findings:
- statement: PPP2CB is a direct target of miR-1246; knockdown increases
p65/NF-kappaB and enhances TNF-mediated inflammatory gene expression in
MSCs.
- id: PMID:28386764
title: Roles of tau protein in health and disease.
findings:
- statement: Review describing PP2A as a major tau phosphatase, with relevance
to tauopathies.
- id: PMID:28514442
title: Architecture of the human interactome defines protein communities and
disease networks.
findings:
- statement: Large-scale interactome study confirming STRIP1 interaction with
PPP2CB.
- id: PMID:32814053
title: Interactome Mapping Provides a Network of Neurodegenerative Disease
Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
findings:
- statement: Identified PPP2CB-FMR1 interaction in neurodegenerative disease
protein network.
- id: PMID:33961781
title: Dual proteome-scale networks reveal cell-specific remodeling of the
human interactome.
findings:
- statement: Cell-specific interactome confirming IGBP1 and STRIP1
interactions with PPP2CB.
- id: PMID:35271311
title: 'OpenCell: Endogenous tagging for the cartography of human cellular organization.'
findings:
- statement: Endogenous tagging proteomics confirming IGBP1 and STRIP1
interactions with PPP2CB.
- id: Reactome:R-HSA-1295599
title: SPRY2 translocates to the plasma membrane
findings: []
- id: Reactome:R-HSA-1295609
title: SRC phosphorylates SPRY2 on Y55 and Y227
findings: []
- id: Reactome:R-HSA-1295613
title: SPRY2 binds GRB2
findings: []
- id: Reactome:R-HSA-1295622
title: SPRY2 binds CBL
findings: []
- id: Reactome:R-HSA-1295632
title: PPA2A dephosphorylates SPRY2
findings: []
- id: Reactome:R-HSA-1549564
title: PPTN11 dephosphorylates SPRY2
findings: []
- id: Reactome:R-HSA-934559
title: SPRY2 is phosphorylated by phosphorylated MNK1
findings: []